Alexander Koch1, Daniel H Schanne2, Gunar Günther3,4, Daniel M Aebersold2, Olgun Elicin2. 1. Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. alexander.koch@insel.ch. 2. Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 3. Department of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 4. Department of Medical Sciences, UNAM School of Medicine, University of Namibia, Windhoek, Namibia.
Abstract
PURPOSE: Chronic pulmonary aspergillosis (CPA) can manifest as fungus balls in preexisting cavities of lung parenchyma and recurrent hemoptysis is among the most frequent complications. Radiotherapy can be considered for treatment-refractory aspergilloma and severe hemoptysis. To the best of our knowledge, we present the first application of stereotactic body radiotherapy (SBRT) for a pulmonary aspergilloma in a patient with limited functional lung capacity. The topic was further expanded on with a systematic review of the literature addressing the implementation of radiotherapy in CPA patients. CASE REPORT: A 52-year-old man presented with recurring and treatment-refractory hemoptysis caused by chronic cavitary aspergillosis localized in the left lower lobe. We applied SBRT on two consecutive days with a total dose of 16 Gy. Hemoptysis frequency decreased to a clinically insignificant level. SYSTEMATIC REVIEW: We performed a systematic search of the literature in line with the PRISMA statement. The initial PubMed search resulted in 230 articles, of which 9 were included. RESULTS: The available literature contained 35 patients with CPA who received radiotherapy. Dose fractionation usually ranged from 2 to 4 Gy per fraction, applied almost exclusively in conventional two-dimensional (2D) techniques. There is no report of SBRT usage in such a scenario. Most cases report a positive treatment response after irradiation. CONCLUSION: The presented case demonstrates long-term clinical stability after SBRT for recurrent hemoptysis due to pulmonary aspergilloma. The systematic literature search revealed that concept definition is still uncertain, and further work is necessary to establish radiotherapy in clinical practice.
PURPOSE: Chronic pulmonary aspergillosis (CPA) can manifest as fungus balls in preexisting cavities of lung parenchyma and recurrent hemoptysis is among the most frequent complications. Radiotherapy can be considered for treatment-refractory aspergilloma and severe hemoptysis. To the best of our knowledge, we present the first application of stereotactic body radiotherapy (SBRT) for a pulmonary aspergilloma in a patient with limited functional lung capacity. The topic was further expanded on with a systematic review of the literature addressing the implementation of radiotherapy in CPA patients. CASE REPORT: A 52-year-old man presented with recurring and treatment-refractory hemoptysis caused by chronic cavitary aspergillosis localized in the left lower lobe. We applied SBRT on two consecutive days with a total dose of 16 Gy. Hemoptysis frequency decreased to a clinically insignificant level. SYSTEMATIC REVIEW: We performed a systematic search of the literature in line with the PRISMA statement. The initial PubMed search resulted in 230 articles, of which 9 were included. RESULTS: The available literature contained 35 patients with CPA who received radiotherapy. Dose fractionation usually ranged from 2 to 4 Gy per fraction, applied almost exclusively in conventional two-dimensional (2D) techniques. There is no report of SBRT usage in such a scenario. Most cases report a positive treatment response after irradiation. CONCLUSION: The presented case demonstrates long-term clinical stability after SBRT for recurrent hemoptysis due to pulmonary aspergilloma. The systematic literature search revealed that concept definition is still uncertain, and further work is necessary to establish radiotherapy in clinical practice.
Authors: David W Denning; Jacques Cadranel; Catherine Beigelman-Aubry; Florence Ader; Arunaloke Chakrabarti; Stijn Blot; Andrew J Ullmann; George Dimopoulos; Christoph Lange Journal: Eur Respir J Date: 2016-01 Impact factor: 16.671
Authors: A J Ullmann; J M Aguado; S Arikan-Akdagli; D W Denning; A H Groll; K Lagrou; C Lass-Flörl; R E Lewis; P Munoz; P E Verweij; A Warris; F Ader; M Akova; M C Arendrup; R A Barnes; C Beigelman-Aubry; S Blot; E Bouza; R J M Brüggemann; D Buchheidt; J Cadranel; E Castagnola; A Chakrabarti; M Cuenca-Estrella; G Dimopoulos; J Fortun; J-P Gangneux; J Garbino; W J Heinz; R Herbrecht; C P Heussel; C C Kibbler; N Klimko; B J Kullberg; C Lange; T Lehrnbecher; J Löffler; O Lortholary; J Maertens; O Marchetti; J F Meis; L Pagano; P Ribaud; M Richardson; E Roilides; M Ruhnke; M Sanguinetti; D C Sheppard; J Sinkó; A Skiada; M J G T Vehreschild; C Viscoli; O A Cornely Journal: Clin Microbiol Infect Date: 2018-03-12 Impact factor: 8.067
Authors: Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher Journal: BMJ Date: 2021-03-29